JPMorgan lowered the firm’s price target on Eli Lilly (LLY) to $1,050 from $1,100 and keeps an Overweight rating on the shares. The firm left its large cap biopharma estimates largely unchanged but adjusted price targets on a move to December 2026 from December 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Stock (NVO) Rises After Triple-Dose Trial Hits 19% Weight Loss
- Eli Lilly’s New Phase 3 Study: A Potential Game-Changer in Advanced Breast Cancer Treatment
- Option traders moderately bearish in Eli Lilly with shares down 0.87%
- Time to Bet on Hims & Hers Health (HIMS)? Analysts Point to Several Growth Catalysts
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots